In NAVIGATE ESUS (New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial Versus ASA to Prevent Embolism in Embolic Stroke of Undetermined Source) [71] and RE-SPECT ESUS (Randomized, Double-Blind Evaluation in Secondary Stroke Prevention Comparing the Efficacy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate Versus Acetylsalicylic Acid in Patients with Embolic Stroke of Undetermined Source), stroke severity was similarly low (Stroke Scale score 1) [72]. This evidence concerns the gene F10 and Stroke.